Clinical Trial: Shockwave Coronary Lithoplasty Study

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Early Safety and Feasibility Study of the Shockwave Coronary Lithoplasty™ System in Coronary Arteries

Brief Summary: The objective of this clinical trial is to study the early safety and feasibility of the Shockwave Coronary Lithoplasty System. To demonstrate that the Shockwave device can safely and effectively deliver localized shockwave energy for balloon dilatation of calcified, stenotic, de novo coronary lesions.

Detailed Summary: Prospective, non-randomized, single center First In Human (FIH) trial for treatment of stenotic calcified coronary lesions with the Shockwave Lithoplasty System. Patients will be enrolled and consented in the study based on history and in some instances an angiogram obtained prior to the study. The study is designed to demonstrate that the Shockwave device can safely and effectively deliver localized shockwave energy for balloon dilatation of calcified, stenotic, coronary arteries. Subjects will be prepared for PCI per the institution's standard protocol. Medications will be administered per the treatment protocol. Femoral access will be obtained using a 6F access sheath, and guiding catheter placed at the ostia of the right or left coronary artery. Baseline angiography of the culprit lesion will be performed prior to placement of a 0.014" guide wire. Baseline and either IVUS or OCT will be performed to determine the Maximum Lumen Area (MLA), percent stenosis, and volumetric lesion assessment. Baseline angiography will be performed to determine lesion length, % stenosis and reference vessel diameter. The investigational device will be prepped per the IFU and positioned at the target lesion. The distal end of the balloon catheter will be connected to the patient cable. The balloon catheter will be inflated to 4 atm and the investigator will deliver 10 pulses for 20 seconds. The balloon will then be inflated to reference vessel diameter and then deflated to reestablish flow and complete one treatment cycle. The treatment cycle will then be repeated. Angiography and either IVUS or OCT will be repeated for the treated lesion.. A coronary stent will be deployed at the site of treatment. Angiography and either IVUS or OCT will be performed following stent placement. Patients will be followed through discharge and at 30 and 180 days. A subset of up to five (5) subjects will receive an angiographic assessment at the 180 day follow up visit, per the Sponsor's discretion
Sponsor: Shockwave Medical, Inc.

Current Primary Outcome:

  • Safety - Acute, as indicated by number of subjects that do not experience death following delivery of shockwave energy [ Time Frame: Post-procedure (within 24 hours following procedure) ]
  • Safety - Acute, as indicated by number of subjects that do not experience tamponade following delivery of shockwave energy [ Time Frame: Post-procedure (within 24 hours following procedure) ]
  • Safety - Acute, as indicated by number of subjects that do not experience dissection, occlusion or perforation of the coronary artery that requires additional intervention to treat besides stenting following delivery of shockwave energy [ Time Frame: Post-procedure (within 24 hours following procedure) ]
  • Safety - Acute, as indicated by number of subjects that do not experience aneurysm following delivery of shockwave energy [ Time Frame: Post-procedure (within 24 hours following procedure) ]
  • Safety - Acute, as indicated by number of subjects that do not experience MI (CPK > 5 x uln) following delivery of shockwave energy [ Time Frame: Post-procedure (within 24 hours following procedure) ]
  • Safety - Acute, as indicated by number of subjects that do not experience cardiogenic shock following delivery of shockwave energy [ Time Frame: Post-procedure (within 24 hours following procedure) ]
  • Safety - Acute, as indicated by number of subjects that do not experience distal embolization compromising blood flow, and requiring intervention following delivery of shockwave energy [ Time Frame: Post-procedure (within 24 hours following procedure) ]
  • Safety - Acut

    Original Primary Outcome: Same as current

    Current Secondary Outcome:

    Original Secondary Outcome:

    Information By: Shockwave Medical, Inc.

    Dates:
    Date Received: January 16, 2015
    Date Started: July 2014
    Date Completion:
    Last Updated: April 27, 2016
    Last Verified: April 2016